Background and aims
Guillain-Barré syndrome is an acute polyradiculoneuropathy which is immune mediated. It’s considered as a life-threatening by the respiratory affection and the dysautonomia. It is commonly reported as an adverse event after compylobacter Jejuni infection and following vaccination.
Methods
We report two cases of GBS, after receiving the first dose of Astrazeneca COVID-19 vaccine.
Results
Cases description: First case of a 70 years old woman, presenting progressive, symmetric, ascending flaccid tetraparesis with bladder dysfunction which have occurred three weeks after the first dose of Astrazeneca COVID-19 vaccine. The cerebrospinal fluid showed an albuminocytologic dissociation, electrophysiological studies showed an acute inflammatory demyelinating polyradiculoneuropathy. Second case of a 68 years old woman, presenting three weeks after the first dose of Astrazeneca COVID-19 vaccine a progressively descending, symmetrical and synchronous tetraplegia, preceding 4 days before by diffuse headaches with multiple cranial pairs affection and bladder dysfunction. The cerebrospinal fluid showed an albuminocytologic dissociation, electrophysiological studies showed an acute inflammatory axonal and demyelinating polyradiculoneuropathy.
Conclusion
Many cases of GBS after vaccines has been reported including one case following Pfizer COVID-19 vaccine, yet the physiopathological mechanisms are not completely elucidated.
